Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Clinical application of a rapid, functional assay for multidrug resistance based on accumulation of the fluorescent dye, fluo-3D M Wall, R Sparrow, X F Hu, et al.
Journal of the American College of Cardiology|July 14, 2001
Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. LIPID Study InvestigatorsI C Marschner, D Colquhoun, R J Simes, et al.
Journal of the Royal Society, Interface|February 25, 2011
Estimating reproduction numbers for adults and children from case dataK Glass, G N Mercer, H Nishiura, et al.
BMJ (Clinical Research Ed.)|July 28, 1990
Sexual transmission of hepatitis C virus: cohort study (1981-9) among European homosexual menM Melbye, R J Biggar, P Wantzin, et al.
The Journal of Infectious Diseases|February 1, 1995
Lombok Hepatitis B Model Immunization Project: toward universal infant hepatitis B immunization in IndonesiaT A Ruff, D M Gertig, B F Otto, et al.
The New England Journal of Medicine|October 29, 1998
Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 TeamD V Havlir, I C Marschner, M S Hirsch, et al.
BMJ (Clinical Research Ed.)|November 8, 2003
Deep vein thrombosis and air travel: record linkage studyC W Kelman, M A Kortt, N G Becker, et al.
AIDS (London, England)|September 13, 2000
Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370D R Kuritzkes, R L Bassett, V A Johnson, et al.
Epidemiology and Infection|January 22, 2008
Risk factors for infection with Campylobacter jejuni flaA genotypesL E Unicomb, L C O'Reilly, M D Kirk, et al.
The Journal of Infectious Diseases|January 7, 1998
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapyI C Marschner, A C Collier, R W Coombs, et al.
Pageof 8